Heidelberg Pharma AG provided earnings guidance for the year 2021. The group expects to generate between EUR 5.5 million and EUR 7.5 million in sales revenue and other income (2020: EUR 9.6 million) for the 2021 fiscal year. Loss before interest and tax in the 2021 fiscal year are expected to be between EUR 30 million and EUR 34 million.